Over the past few years, the phenomenon of new designer drugs has attracted much attention. Synthetic cannabinoids and cathinones are the two main classes of these drugs. Both are potent drugs of abuse, and several cases of severe toxicity and deaths are reported. The present work is based on a systematic review of studies that have assessed the market and prevalence of synthetic cannabinoids and cathinones, and integrates pharmacological, sociological, and epidemiological aspects of these two groups of emerging synthetic drugs. The review reflects that the Internet has made synthetic cannabinoids and cathinones widely available. Furthermore, aggressive and widespread marketing, as well as the low price level of these drugs, their juridical status and their lack of detection on standard drug tests may serve as major motivations for drug use. The number of prevalence studies is small and derived from a limited number of countries. In spite of the many methodological shortcomings, some conclusions may be cautiously drawn. Taken together, the results point toward higher prevalence of use for synthetic cathinones than for synthetic cannabinoids. In the general population, the prevalence of use of synthetic cathinones is reported to be around 4% compared to figures lower than 1% for synthetic cannabinoids. Among students, the prevalence varies from 1-20% for synthetic cathinones and 2-10% for synthetic cannabinoids. Among groups with high rates of drug use, the prevalence varies between 4% to more than 60% for synthetic cathinones and around 10% for synthetic cannabinoids.
Download full-text PDF |
Source |
---|
Cureus
December 2024
Emergency Medicine, Memorial Healthcare System, Hollywood, USA.
A six-year-old boy presented to the pediatric emergency department following an accidental ingestion of a synthetic cannabinoid. The child ingested an edible product containing tetrahydrocannabinol (THC) and presented with lethargy, altered mental status, and increased muscle tone. The airway was protected, and the patient was breathing spontaneously.
View Article and Find Full Text PDFMagn Reson Chem
January 2025
Institute of Pharmaceutical Sciences, Department of Pharmaceutical Chemistry, University of Graz, Graz, Austria.
Besides classic illegal drugs, numerous designer drugs, also called new psychoactive substances (NPSs), are available on the global drug market. One of the biggest and fastest-growing substance classes comprises the synthetic cannabinoids. According to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 254 out of 950 monitored substances belong to this group of NPS, with 9 new cannabinoids registered for the first time in 2023.
View Article and Find Full Text PDFBrief Bioinform
November 2024
School of Science, China Pharmaceutical University, Nanjing 211198, China.
The supervision of novel psychoactive substances (NPSs) is a global problem, and the regulation of NPSs was heavily relied on identifying structural matches in established NPSs databases. However, violators could circumvent legal oversight by altering the side chain structure of recognized NPSs and the existing methods cannot overcome the inaccuracy and lag of supervision. In this study, we propose a scaffold and transformer-based NPS generation and Screening (STNGS) framework to systematically identify and evaluate potential NPSs.
View Article and Find Full Text PDFChemosphere
December 2024
School of Engineering, China Pharmaceutical University, Nanjing 210009, China. Electronic address:
Methyl 2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate (5F-ADB), which is classified as an illicit drug in China and most European countries, is susceptible to abuse. The abuse of 5F-ADB must avoid entering the water environment. However, the aquatic toxic effects of 5F-ADB remain unclear.
View Article and Find Full Text PDFCan J Aging
December 2024
Department of Psychology and Centre on Aging and Health, University of Regina, Regina, SK, Canada.
The purpose of the current study was to understand the prevalence and patterns of cannabinoid use among LTC residents across Canada. We gathered data on cannabinoid prescriptions among LTC residents for one year before and after recreational cannabis legalization. Multi-level modelling was used to examine the effects of demographic and diagnostic characteristics on rates of cannabinoid prescription over time.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!